Role of Cytoreductive Nephrectomy Unclear for Dedifferentiated Kidney Cancer
(MedPage Today) -- AUSTIN, Texas -- Cytoreductive nephrectomy improved overall survival (OS) by more than a year for patients with metastatic renal cell carcinoma (mRCC) with sarcomatoid or rhabdoid (S/R) dedifferentiation treated with immunotherapy... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 10, 2022 Category: Hematology Source Type: news
Immune Stimulator May Enhance Targeted Therapy's Activity in Metastatic RCC
(MedPage Today) -- AUSTIN, Texas -- A dendritic-cell immune primer failed to meet survival endpoints in a randomized trial of high-risk synchronous metastatic renal cell carcinoma (mRCC) but nonetheless showed evidence of activity.
The 18-month... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 9, 2022 Category: Hematology Source Type: news
Episode 4: The Microbiome and Renal Cell Carcinoma Episode 4: The Microbiome and Renal Cell Carcinoma
Drs Sumanta Pal and Jennifer Wargo discuss how the gut microbiome impacts response to cancer therapy in patients with renal cell carcinoma.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 2, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Episode 3: Non-Clear Cell Renal Cell Carcinoma Episode 3: Non-Clear Cell Renal Cell Carcinoma
Drs Sumanta Pal and Mehmet Asim Bilen discuss the complexities of treating patients with non-clear cell renal carcinoma, the nuances of rare subtypes, and when to use chemotherapy vs immunotherapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Updates in Renal Cell Carcinoma From ESMO 2022 Updates in Renal Cell Carcinoma From ESMO 2022
Positive results with triplet therapy, three adjuvant immunotherapy failures, and promising novel combinations are some of the updates from ESMO Congress 2022 discussed by Dr Eric Jonasch.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 30, 2022 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news
Triplet Therapy Ups Progression - Free Survival in Advanced Kidney Cancer
PFS improved with cabozantinib + nivolumab + ipilimumab for patients with previously untreated advanced renal cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 27, 2022 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Conference News, Source Type: news
Triplet Therapy Ups Progression-Free Survival in Advanced Kidney Cancer
MONDAY, Sept. 26, 2022 -- Triplet therapy of cabozantinib + nivolumab + ipilimumab significantly improves progression-free survival (PFS) compared with placebo + nivolumab + ipilimumab for patients with previously untreated advanced renal cell... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 27, 2022 Category: Pharmaceuticals Source Type: news
Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCC
WEDNESDAY, Sept. 14, 2022 -- Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy relapse,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2022 Category: Pharmaceuticals Source Type: news
Triplet in First-Line Kidney Cancer Thwarts Disease Progression
(MedPage Today) -- PARIS -- Adding the tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) to dual immune checkpoint inhibition improved progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), the phase III... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2022 Category: Hematology Source Type: news
Cabozantinib Boosts Dual Immunotherapy in Advanced RCC Cabozantinib Boosts Dual Immunotherapy in Advanced RCC
Triplet therapy for advanced renal cell carcinoma may soon be an option, after results show that adding cabozantinib to dual immune checkpoint inhibition improved progression-free survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 12, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma
(MedPage Today) -- PARIS -- While pembrolizumab (Keytruda) has been approved as an adjuvant treatment for patients with high-risk renal cell carcinoma (RCC), three phase III studies presented at the European Society for Medical Oncology (ESMO... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 12, 2022 Category: Hematology Source Type: news
Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro
Six months of adjuvant nivolumab plus ipilimumab after nephrectomy for renal cell carcinoma offers no disease-free survival benefit, reveals trial that highlights treatment duration and tolerability.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Checkpoint Inhibitor Combos Show Promise in Advanced RCC Checkpoint Inhibitor Combos Show Promise in Advanced RCC
First-line therapy for renal cell carcinoma has primarily been tyrosine kinase inhibitors that target vascular endothelial growth factor and other receptors.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 1, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Cabozantinib Combined With Atezolizumab for Advanced RCC Cabozantinib Combined With Atezolizumab for Advanced RCC
This novel therapeutic combination shows encouraging results in patients with advanced renal cell carcinoma.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 1, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Mesothelioma Clinical Trial Studies Keytruda, Lenvatinib Combination
The objective response rate of the Keytruda/lenvatinib combination was an impressive 58%.
In 2020, the U.S. Food and Drug Administration approved the use of Keytruda for certain metastatic tumors, including certain cases of mesothelioma, but the search for an effective combination continues.
Lenvatinib has shown it can block tumor growth by targeting specific proteins Keytruda can’t reach. It has been effective with only select cancers and is known as precision medicine.
The drug, which is already FDA approved, has been used successfully with Keytruda for the treatment of endometrial cancer. Lenvatinib is prescr...
Source: Asbestos and Mesothelioma News - August 17, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Pleural Source Type: news
